sponsored
PatientsVille.com Logo

PatientsVille

Protium Medical Research Studies

Up-to-date List of Protium Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Protium Medical Research Studies

Rank Status Study
1 Recruiting Studies of Pandemic Influenza (H1N1) 2009 Vaccine in Bergen
Condition: Healthy
Intervention: Biological: Pandemrix
Outcome Measures: The primary endpoints of the trial are the local and systemic adverse events and tolerability of parenterally administered adjuvanted H1N1 influenza vaccine in all volunteers;   The secondary endpoints are the evaluation of the immunogenicity of adjuvanted H1N1 influenza vaccine and the ability of the vaccine to meet the CHMP evaluation criteria in a subset of volunteers
2 Unknown  Antibody Titer Analysis After H1N1 Vaccination in Pediatric Haemato-oncology Patients
Conditions: Serology Analysis;   Novel H1N1 Influenza Vaccination;   Pediatric Haemato-oncology Patients
Intervention: Biological: Influenza A (H1N1) 2009 monovalent vaccine, inactivated
Outcome Measures: This study is designed to investigate the antibodies titers before and after the novel H1N1 influenza vaccination in these patients. Titer of H1N1 influenza virus antibodies will be determined by hemagglutinin inhibition assay (HAI).;   If the patient presents influenza-like symptoms during the six month follow up period, we will perform throat swab or nasal swab for influenza rapid test, viral isolation, and novel H1N1 influenza PCR to confirm the diagnosis.
3 Recruiting Influenza A H1N1: Retrospective Analysis of PCR Confirmed Cases of H1N1 Infections in Styria - Risk Factors, Clinical Features and Outcome.
Condition: Clinically Suspected H1N1 Infection
Intervention:
Outcome Measure: clinical presentation of H1N1 compared to other viral infections
4 Recruiting Treatment of Bipolar Depression With H1-Coil Deep Brain rTMS: Clinical-Cognitive and Safety Evaluation
Condition: Bipolar Depression
Intervention: Device: Deep Brain Transcranial Magnetic Stimulation
Outcome Measures: Hamilton Rating Scale for Depression, 17 items (HAMD17);   Young Mania Rating Scale (11 items)
5 Recruiting Methotrexate in the Treatment of Chronic Idiopathic Urticaria
Condition: Chronic Urticaria
Interventions: Drug: Methotrexate (Novatrex ®) + anti-H1;   Drug: Placebo + anti-H1
Outcome Measures: Number of patients with complete remission of urticaria at 18 weeks;   Tolerance : clinical and biological safety;   Efficacy of the treatment in improving symptoms : pruritus;   Persistency of the complete remission at 26 weeks;   Efficacy of the treatment in improving symptoms : outbreaks by week;   Efficacy of the treatment in improving symptoms : duration of lesions;   Efficacy of the treatment in improving quality of life;   Efficacy of the treatment in improving quality of sleep;   Efficacy of the treatment in improving facial/cervical urticarial lesions
6 Unknown  A Pragmatic Randomized Controlled Trial of Chinese Herbal Medicine for Severe Pandemic H1N1 Influenza
Condition: Influenza A Virus, H1N1 Subtype
Interventions: Drug: Chinese herbal medicines plus western therapy;   Drug: western therapy
Outcome Measures: incidence of complication;   mortality of pandemic H1N1 influenza and all-cause mortality(only for severe pandemic H1N1 influenza patients);   proportion of deteriorating into severe H1N1 influenza (only for pandemic H1N1 influenza patients with risk factors for severe H1N1 influenza);   time to allaying a fever;   time to symptom relief;   time and proportion of H1N1 virus turning to negative;   direct medical cost;   safety outcome(adverse effects);   days in hospital;   dose and usage of hormones(only for severe pandemic H1N1 influenza patients);   Inflammation of lung tissue(only for severe pandemic H1N1 influenza patients)
7 Recruiting Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.
Condition: Glioblastoma Multiforme
Intervention: Drug: H-1PV
Outcome Measures: Safety and tolerability;   Efficacy (treatment response)
8 Unknown  Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month
Conditions: Influenza;   Swine-origin A/H1N1 Influenza
Interventions: Biological: 7.5ug H1N1 Influenza vaccine;   Biological: 15ug H1N1 vaccine;   Biological: seasonal influenza vaccine
Outcome Measure:
9 Recruiting Stem Cell Transplant for Hematologic Diseases
Condition: Hematologic Malignancies
Interventions: Biological: Campath 1H;   Drug: Fludarabine;   Procedure: Stem Cell Transplant;   Radiation: Total Body Irradiation (TBI);   Drug: FK506 (Tacrolimus) or Cyclosporin
Outcome Measures: Treatment-related mortality of haploidentical allogeneic stem cell transplantation with non-myeloablative therapy incorporating Campath 1H.;   Time to engraftment and incidence of graft failure.;   Safety, pharmacokinetics, and immunologic activity of Campath 1H.;   Clinical comparison of CLINIMACSs CD34 Reagent System and Isolex System.
10 Recruiting Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis
Condition: Scleroderma
Intervention:
Outcome Measures: Primary outcome;   Campath
11 Unknown  Vaccination Against Influenza H1N1 in Rheumatic Diseases
Conditions: Influenza;   Rheumatic Diseases
Intervention: Biological: Focetria (Monovalent MF59-Adjuvanted vaccine)
Outcome Measures: Primary Endpoint : Proportion of patients who will achieve a titer of antibodies above 1/40 within the groups of patients in comparison with healthy subjects;   Secondary Endpoint: Safety of the vaccine with regard to disease activity by changes in DAS, SLEDAI and BASDAI
12 Recruiting Deep rTMS for Treatment-Resistant Late-life Depression
Condition: Major Depressive Disorder
Interventions: Device: Brainsway H1-Coil Deep TMS System (Sham treatment);   Device: Brainsway H1-Coil Deep TMS System
Outcome Measures: HDRS-24;   Mean change in HDRS-24
13 Unknown  Antibody Levels Against 2009 Influenza A H1N1 One Year After Vaccination With Pandemrix and 2010 Fluarix Booster in Organ Transplant Recipients.
Condition: Organ Transplantation
Intervention:
Outcome Measures: Frequency of individuals with remaining protective antibody titers against influenza H1N1 2009 one year after Pandemrix vaccination in organ transplant patients and controls;   Booster effect on antibody titers against influenza 2009 H1N1 of 2010 Fluarix vaccination
14 Unknown  The Impact of Vitamin on the Clinical Course in Cases Infected by Novel H1N1 Influenza Virus A
Condition: H1N1 Influenza
Interventions: Drug: Vitamin (vitamin A 15 mg,C 500 mg, E 400IU);   Drug: Placebo (digestive tablet)
Outcome Measure: change of symptom score
15 Recruiting Clinical Characteristics and Outcomes in Patients Diagnosed With Novel Influenza A (H1N1)
Condition: Influenza
Intervention:
Outcome Measures: To describe the clinical characteristic and outcomes of the patients admitted to UPMC Presbyterian campus with infection due to novel influenza A (H1N1).;   To identify risk factors for admission to the ICU and mortality
16 Unknown  Antibody Production Following H1N1 Influenza Vaccination After Stem Cell and Heart Transplantation
Condition: H1N1 Influenza
Intervention:
Outcome Measure:
17 Unknown  Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients
Conditions: HIV-1 Infection;   Cancer;   Immunosuppression
Intervention: Other: serologic testing
Outcome Measures: To investigate the immunogenicity via anti-hemagglutinin responses following an adjuvanted H1N1 vaccination in HIV-positive and immunosuppressed adult patients;   To evaluate the effect of pre-existing anti-influenza immunity and recent history of seasonal influenza and H5N1 vaccination on seroresponses to the H1N1 influenza vaccine;   To evaluate potential adverse reactions of the H1N1 vaccine
18 Unknown  Risk of Narcolepsy Associated With Administration of H1N1 Vaccine
Condition: Narcolepsy
Intervention: Other: No intervention
Outcome Measure: Risk of narcolepsy among vaccinated and non-vaccinated persons, adjusting for age and sex using the Mantel-Haenszel method
19 Recruiting Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome
Conditions: Mycosis Fungoides;   Sezary Syndrome
Intervention: Drug: Campath-1H
Outcome Measures: The primary goal is to find the minimal dose of conditioning regimen (of the two considered) which will establish engraftment in greater than 80% of patients.;   Assess donor-host chimerism in various hematopoietic and lymphoid cells, dx response, incidence of acute/chronic GVHD, graft failure, assessment of lymphoid subset reconstitution, transplant related morbidity/mortality and dx-free and survival.
20 Unknown  Effectiveness of H1N1 Influenza Vaccines in Manitoba, Canada
Conditions: Influenza;   Pneumonia
Intervention:
Outcome Measures: Hospitalization with laboratory-confirmed influenza or pneumonia;   Hospitalization with influenza or pneumonia

These studies may lead to new treatments and are adding insight into Protium etiology and treatment.

A major focus of Protium research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Protium